Alexia D. Katsarou

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

CXXC1-dependent IRF4 activity promotes myeloma cell fitness and sustains lenalidomide resistance.

CXXC1-dependent IRF4 activity promotes myeloma cell fitness and sustains lenalidomide resistance.

Journal: Blood

Published: February 04, 2026

MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis.

MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis.

Journal: Blood advances

Published: January 17, 2023

Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma.

Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma.

Journal: Blood

Published: October 12, 2021

Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia.

Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia.

Journal: Science translational medicine

Published: September 13, 2021

Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.

Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.

Journal: Trials

Published: March 11, 2021

The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma.

The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma.

Journal: Haematologica

Published: October 20, 2020

Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.

Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.

Journal: Nature communications

Published: October 05, 2020

Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in vitro.

Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in vitro.

Journal: iScience

Published: October 02, 2020

Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.

Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.

Journal: British journal of haematology

Published: April 27, 2020

A novel mutation in exon 2 of FGB caused by c.221G>T † substitution, predicting the replacement of the native Arginine at position 74 with a Leucine (p.Arg74Leu † ) in a proband from a Kurdish family with dysfibrinogenaemia and familial venous and arterial thrombosis.

A novel mutation in exon 2 of FGB caused by c.221G>T † substitution, predicting the replacement of the native Arginine at position 74 with a Leucine (p.Arg74Leu † ) in a proband from a Kurdish family with dysfibrinogenaemia and familial venous and arterial thrombosis.

Journal: Journal of thrombosis and thrombolysis

Published: November 05, 2016

Showing 1-10 of 10

Last Updated: 09/26/2026